A Placebo-Controlled, Single-Blind, Randomised, Parallel Group, 28-Day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 [NS-2359] in Healthy Young and Elderly, Male and Female Subjects.

Trial Profile

A Placebo-Controlled, Single-Blind, Randomised, Parallel Group, 28-Day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 [NS-2359] in Healthy Young and Elderly, Male and Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2011

At a glance

  • Drugs NS 2359 (Primary)
  • Indications Depressive disorders
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 23 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top